Skip to content

EU · EudraLex Vol.4

EU GMP Annex 1 8.132

8. Production and Specific Technologies › Single use systems (SUS)

Section text

There are some specific risks associated with SUS which should be assessed as part of the CCS. These risks include but are not limited to:

i. The interaction between the product and product contact surface (such as adsorption, or leachables and extractables).

ii. The fragile nature of the system compared with fixed reusable systems.

iii. The increase in the number and complexity of manual operations (including inspection and handling of the system) and connections made.

iv. The complexity of the assembly.

v. The performance of the pre- and post-use integrity testing for sterilising grade filters (see paragraph 8.87).

vi. The risk of holes and leakage.

vii. The potential for compromising the system at the point of opening the outer packaging.

viii. The risk of particle contamination.

Source: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · retrieved 2026-11-15

Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.